Chemiluminescent activity and platelet aggregation in chronic coronary heart disease on acetylsalicylic acid therapy before and after coronary bypass surgery
Keywords:
chronic coronary disease, resistance, acetylsalicylic acid, platelet, chemiluminescence, reactive oxygen species
Abstract
Introduction. Some patients after coronary artery bypass grafting (CABG) may be resistant to acetylsalicylic acid (ASA) used as an antiplatelet agent. The mechanisms of this condition are still under discussion. We studied the functional activity of ASA-resistant and -sensitive platelets using a chemiluminescent (CL) analysis. Methods. 104 patients with chronic coronary disease (CCD) were evaluated. The control group consisted of 30 healthy donors. Blood sampling was performed prior to CABG and at one and 8-10 days after CABG. Platelet aggregation with collagen, adrenaline, and ADP and platelet resistance to ASA were determined by optical aggregometry with arachidonic acid at a level ≥20%. Spontaneous and ADP-induced CL of platelets with luminol and lucigenin was studied with a biochemiluminescence analyzer. Results. 71 patients with CCD were found to be sensitive to ASA (sASA) whereas 33 patients were resistant to ASA (rASA). Most of CL indexes were higher in sASA patients than in the control group during the entire observation period; in rASA patients, values of these indexes were at the control level. Pre-CABG values of CL indexes were higher in rASA patients than in sASA patients. Lucigenin-enhanced CL was decreased in rASA patients on the first day after CABG and increased on days 8-10 compared to the preoperative level. CL indexes positively correlated with platelet aggregation in rASA patients. Conclusion. The CL method allows assessing the functional activity of platelets in CCD. The study of CL indexes may identify rASC patients before the CABG surgery. The dynamics of CL index values in sASK patients before and after surgery and the absence of such dynamics in patients with rASC suggests that aspirin resistance depends not only on the internal condition of platelets but also on intercellular relations.
Downloads
Download data is not yet available.
References
1. Zherdev N. N. ESC/EACTS recommendations for myocardial revascularization 2018. Adapted translation into Russian: Russian Society of Cardiology. Rossiyskiy kardiologicheskiy zhurnal. 2019; 24(8): 151-226. (in Russian)
2. Wang M.M., Xue M., Xu Y.G., Miao Y., Kou N., Yang L. et al. Panax notoginseng saponin is superior to aspirin in inhibiting platelet adhesion to injured endothelial cells through COX pathway in vitro. Thrombosis research. 2016; 141: 146-152.
3. Macchi L., Sorel N., Christiaens L. Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Current pharmaceutical design. 2006; 12(2): 251-258.
4. Grinshtein I.Yu., Savchenko A.A., Grinshtein Yu.I., Savchenko E.A., Petrova M.M. Activity of NAD- and NADP-dependent platelet dehydrogenases in aspirin-resistant patients with stable angina pectoris. Sibirskoe meditsinskoe obozrenie. 2013; 3: 33-36. (in Russian)
5. Grinshtein Yu.I., Savchenko E.A., Filonenko I.V., Grinshtein I.Yu., Savchenko A.A. Zyllt in coronary atherosclerosis patients after coronary artery bypass graft surgery. Preliminary results of an open, randomized, comparative ZEUS Study. Kardiovaskulyarnaya terapiya i profilaktika. 2008; 7(6): 43-49. (in Russian)
6. Politidis R.R., Lyang O.V., Kobelevskaya N.V., Ogurtsov P.P., Kochetov A. G. Clinical and laboratory predictors of the development of aggregation aspirin resistance in patients with coronary artery disease. Vestnik poslediplomnogo meditsinskogo obrazovaniya. 2017; 4: 55-63. (in Russian)
7. Komarov A.L., Panchenko E.P. Testing platelet function to assess the risk of thrombosis and bleeding in patients with coronary artery disease receiving antiplatelet drugs. Rossiyskiy kardiologicheskiy zhurnal. 2015; 3(119): 25-34. (in Russian)
8. Zhang P., Du J., Zhao L., Wang X., Zhang Y., Yan R. Et al. The role of intraplatelet reactive oxygen species in the regulation of platelet glycoprotein Ibα ectodomain shedding. Thrombosis research. 2013; 132(6): 696-701.
9. Pozhilova E.V., Novikov V.E., Levchenkova O.S. Reactive oxygen species in cell physiology and pathology. Vestnik Smolenskoy gosudarstvennoy meditsinskoy akademii. 2015; 14(2): 13-22. (in Russian)
10. Vladimipov Yu.A., Ppockupnina E.V., Izmaylov D.Yu. Kinetic chemiluminescence as a method for studying the reactions of free radicals. Biofizika. 2011; 56(6): 1081–1090. (in Russian)
11. Krivokhizhina L.V., Kantyukov S.A., Ermolaeva E.N., Krivokhizhin D.N. Platelet chemiluminescence. Using the chemiluminescence method to determine the activity of platelets. Vestnik Tyumenskogo gosudarstvennogo universiteta. Mediko-biologicheskie nauki. 2013; 6: 174-181. (in Russian)
12. Ryzhkova E.V., Ryazyankina N.B., Lebedeva A.M., Albakova T.M., Albakova R.M., Gabbasov Z.A. i dr. Platelet chemiluminescence and endothelial dysfunction in patients with acute myocardial infarction. Kreativnaya kardiologiya. 2016; 10(3): 195-200. (in Russian)
13. Grinshtein Yu.I., Filonenko I.V., Savchenko A.A., Savchenko E.A., Grinshtein I.Yu. Method for diagnosing acetylsalicylic acid resistance. Patent 2413953, RF; 2009. (in Russian)
14. Savchenko E.A., Savchenko A.A., Gerasimchuk A.N., Grishchenko D.A.
Assessment of the metabolic status of platelets in health and in ischemic heart disease. Klinicheskaya laboratornaya diagnostika. 2006; 5: 33-36. (in Russian)
15. Savchenko A.A., Goncharov M.D, Grinshtein Yu.I., Gvozdev I.I., Mongush T.S., Kosinova A.A. Analysis of the active oxygen form synthesis by thrombocytes of patients with ischemic heart disease by the chemiluminescent method. Byulleten' eksperimental'noy biologii i meditsiny. 2020; 169(4): 525-528. (in Russian)
16. Lev E.I. Aspirin resistance: transient laboratory finding or important clinical entity? Journal of the American college of cardiology. 2009; 53(8): 678-680.
17. Grinshtein I.Yu., Savchenko A.A., Grinshtein Yu.I., Savchenko E.A. Platelet metabolic features in patients with stable angina regarding aspirin resistant. Kreativnaya kardiologiya. 2014; 8(1): 15-24. (in Russian)
18. Wang T.H., Bhatt D.L., Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. European Heart Journal. 2006; 27 (6): 647-654.
19. Grinshtein Yu.I., Kosinova A.A., Mongush T.S., Goncharov M.D. Bypass grafting: outcomes and efficiency of antiplatelet treatment. Kreativnaya kardiologiya. 2020; 14(2): 138-149. (in Russian)
20. Grosser T., Fries S., Lawson J.A., Kapoor S., Grant G., FitzGerald G. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013; 127(3): 377-385.
21. Puchin'yan N.F., Furman N.V., Malinova L.I., Dolotovskaya P.V. The problem of monitoring the effectiveness of antiplatelet therapy in cardiological practice. Ratsional'naya farmakoterapiya v kardiologii. 2017; 13(1): 107-115. (in Russian)
22. Bauer A., Hausmann H., Schaarschmidt J., Scharpenberg M.,Troitzsch D., Johansen P. et al. Shed-blood-separation and cell-saver: an integral part of MiECC? Shed-blood-separation and its influence on the perioperative inflammatory response during coronary revascularization with minimal invasive extracorporeal circulation systems a randomized controlled trial. Perfusion. 2018; 33(2): 136-147.
23. Kornev V.I., Shelukhin D.A. Haemostasis and minimally invasive extracorporeal circulation. Patologiya krovoobrashcheniya i kardiokhirurgiya. 2019; 23(3): 84-97. (in Russian)
24. Elçi M.E., Kahraman A., Mutlu E., Ispir C. S.. Effects of minimal extracorporeal circulation on the systemic inflammatory response and the need for transfusion after coronary bypass grafting surgery. Cardiology research and practice. 2019; 2019: 1-8.
25. Jenne C.N., Urrutia R., Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. International journal of hematology. 2013; 35(3): 254-261.
26. Sviridova S.P., Somonova O.V., Kashiya Sh.R., Obukhova O.A., Sotnikov A.V. The role of platelets in inflammation and immunity. Issledovaniya i praktika v meditsine. 2018; 5(3): 40-52. (in Russian)
27. Pinegin B.V., Vorob'eva N.V., Pashchenkov M.V., Chernyak B.V. The role of mitochondrial reactive oxygen species in activation of innate immunity. Immunologiya. 2018; 39(4): 221-229. (in Russian)
28. Momot A.P., Tsarigorodtseva N.O., Fedorov D.V., Bishevskiy K.M., Vostrikova N.V., Klimova E.E. Platelet microvesicles and their role in providing hemostatic potential (literature review). Sibirskiy nauchnyy meditsinskiy zhurnal. 2020; 40(2): 4-14. (in Russian)
29. Markova K.L., Kogan I.Yu., Sheveleva A.R., Mikhaylova V.A., Sel'kov S.A., Sokolov D.I. Microvesicles of leukocyte origin. Vestnik RAMN. 2018; 73(6): 378-387. (in Russian)
30. Xiao Y., Gu Y., Purwaha P. Characterization of free radicals formed from COX-catalyzed DGLA peroxidation. Free radical biology and medicine. 2011; 50(9): 1163-1170.
2. Wang M.M., Xue M., Xu Y.G., Miao Y., Kou N., Yang L. et al. Panax notoginseng saponin is superior to aspirin in inhibiting platelet adhesion to injured endothelial cells through COX pathway in vitro. Thrombosis research. 2016; 141: 146-152.
3. Macchi L., Sorel N., Christiaens L. Aspirin resistance: definitions, mechanisms, prevalence, and clinical significance. Current pharmaceutical design. 2006; 12(2): 251-258.
4. Grinshtein I.Yu., Savchenko A.A., Grinshtein Yu.I., Savchenko E.A., Petrova M.M. Activity of NAD- and NADP-dependent platelet dehydrogenases in aspirin-resistant patients with stable angina pectoris. Sibirskoe meditsinskoe obozrenie. 2013; 3: 33-36. (in Russian)
5. Grinshtein Yu.I., Savchenko E.A., Filonenko I.V., Grinshtein I.Yu., Savchenko A.A. Zyllt in coronary atherosclerosis patients after coronary artery bypass graft surgery. Preliminary results of an open, randomized, comparative ZEUS Study. Kardiovaskulyarnaya terapiya i profilaktika. 2008; 7(6): 43-49. (in Russian)
6. Politidis R.R., Lyang O.V., Kobelevskaya N.V., Ogurtsov P.P., Kochetov A. G. Clinical and laboratory predictors of the development of aggregation aspirin resistance in patients with coronary artery disease. Vestnik poslediplomnogo meditsinskogo obrazovaniya. 2017; 4: 55-63. (in Russian)
7. Komarov A.L., Panchenko E.P. Testing platelet function to assess the risk of thrombosis and bleeding in patients with coronary artery disease receiving antiplatelet drugs. Rossiyskiy kardiologicheskiy zhurnal. 2015; 3(119): 25-34. (in Russian)
8. Zhang P., Du J., Zhao L., Wang X., Zhang Y., Yan R. Et al. The role of intraplatelet reactive oxygen species in the regulation of platelet glycoprotein Ibα ectodomain shedding. Thrombosis research. 2013; 132(6): 696-701.
9. Pozhilova E.V., Novikov V.E., Levchenkova O.S. Reactive oxygen species in cell physiology and pathology. Vestnik Smolenskoy gosudarstvennoy meditsinskoy akademii. 2015; 14(2): 13-22. (in Russian)
10. Vladimipov Yu.A., Ppockupnina E.V., Izmaylov D.Yu. Kinetic chemiluminescence as a method for studying the reactions of free radicals. Biofizika. 2011; 56(6): 1081–1090. (in Russian)
11. Krivokhizhina L.V., Kantyukov S.A., Ermolaeva E.N., Krivokhizhin D.N. Platelet chemiluminescence. Using the chemiluminescence method to determine the activity of platelets. Vestnik Tyumenskogo gosudarstvennogo universiteta. Mediko-biologicheskie nauki. 2013; 6: 174-181. (in Russian)
12. Ryzhkova E.V., Ryazyankina N.B., Lebedeva A.M., Albakova T.M., Albakova R.M., Gabbasov Z.A. i dr. Platelet chemiluminescence and endothelial dysfunction in patients with acute myocardial infarction. Kreativnaya kardiologiya. 2016; 10(3): 195-200. (in Russian)
13. Grinshtein Yu.I., Filonenko I.V., Savchenko A.A., Savchenko E.A., Grinshtein I.Yu. Method for diagnosing acetylsalicylic acid resistance. Patent 2413953, RF; 2009. (in Russian)
14. Savchenko E.A., Savchenko A.A., Gerasimchuk A.N., Grishchenko D.A.
Assessment of the metabolic status of platelets in health and in ischemic heart disease. Klinicheskaya laboratornaya diagnostika. 2006; 5: 33-36. (in Russian)
15. Savchenko A.A., Goncharov M.D, Grinshtein Yu.I., Gvozdev I.I., Mongush T.S., Kosinova A.A. Analysis of the active oxygen form synthesis by thrombocytes of patients with ischemic heart disease by the chemiluminescent method. Byulleten' eksperimental'noy biologii i meditsiny. 2020; 169(4): 525-528. (in Russian)
16. Lev E.I. Aspirin resistance: transient laboratory finding or important clinical entity? Journal of the American college of cardiology. 2009; 53(8): 678-680.
17. Grinshtein I.Yu., Savchenko A.A., Grinshtein Yu.I., Savchenko E.A. Platelet metabolic features in patients with stable angina regarding aspirin resistant. Kreativnaya kardiologiya. 2014; 8(1): 15-24. (in Russian)
18. Wang T.H., Bhatt D.L., Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. European Heart Journal. 2006; 27 (6): 647-654.
19. Grinshtein Yu.I., Kosinova A.A., Mongush T.S., Goncharov M.D. Bypass grafting: outcomes and efficiency of antiplatelet treatment. Kreativnaya kardiologiya. 2020; 14(2): 138-149. (in Russian)
20. Grosser T., Fries S., Lawson J.A., Kapoor S., Grant G., FitzGerald G. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013; 127(3): 377-385.
21. Puchin'yan N.F., Furman N.V., Malinova L.I., Dolotovskaya P.V. The problem of monitoring the effectiveness of antiplatelet therapy in cardiological practice. Ratsional'naya farmakoterapiya v kardiologii. 2017; 13(1): 107-115. (in Russian)
22. Bauer A., Hausmann H., Schaarschmidt J., Scharpenberg M.,Troitzsch D., Johansen P. et al. Shed-blood-separation and cell-saver: an integral part of MiECC? Shed-blood-separation and its influence on the perioperative inflammatory response during coronary revascularization with minimal invasive extracorporeal circulation systems a randomized controlled trial. Perfusion. 2018; 33(2): 136-147.
23. Kornev V.I., Shelukhin D.A. Haemostasis and minimally invasive extracorporeal circulation. Patologiya krovoobrashcheniya i kardiokhirurgiya. 2019; 23(3): 84-97. (in Russian)
24. Elçi M.E., Kahraman A., Mutlu E., Ispir C. S.. Effects of minimal extracorporeal circulation on the systemic inflammatory response and the need for transfusion after coronary bypass grafting surgery. Cardiology research and practice. 2019; 2019: 1-8.
25. Jenne C.N., Urrutia R., Kubes P. Platelets: bridging hemostasis, inflammation, and immunity. International journal of hematology. 2013; 35(3): 254-261.
26. Sviridova S.P., Somonova O.V., Kashiya Sh.R., Obukhova O.A., Sotnikov A.V. The role of platelets in inflammation and immunity. Issledovaniya i praktika v meditsine. 2018; 5(3): 40-52. (in Russian)
27. Pinegin B.V., Vorob'eva N.V., Pashchenkov M.V., Chernyak B.V. The role of mitochondrial reactive oxygen species in activation of innate immunity. Immunologiya. 2018; 39(4): 221-229. (in Russian)
28. Momot A.P., Tsarigorodtseva N.O., Fedorov D.V., Bishevskiy K.M., Vostrikova N.V., Klimova E.E. Platelet microvesicles and their role in providing hemostatic potential (literature review). Sibirskiy nauchnyy meditsinskiy zhurnal. 2020; 40(2): 4-14. (in Russian)
29. Markova K.L., Kogan I.Yu., Sheveleva A.R., Mikhaylova V.A., Sel'kov S.A., Sokolov D.I. Microvesicles of leukocyte origin. Vestnik RAMN. 2018; 73(6): 378-387. (in Russian)
30. Xiao Y., Gu Y., Purwaha P. Characterization of free radicals formed from COX-catalyzed DGLA peroxidation. Free radical biology and medicine. 2011; 50(9): 1163-1170.
Published
2021-03-13
How to Cite
Goncharov M., Grinshtein Y., Savchenko A., Kosinova A. Chemiluminescent activity and platelet aggregation in chronic coronary heart disease on acetylsalicylic acid therapy before and after coronary bypass surgery // Patologicheskaya Fiziologiya i Eksperimental’naya Terapiya (Pathological physiology and experimental therapy). 2021. VOL. 65. № 1. PP. 42–51.
Issue
Section
Original research
